TY  - JOUR
A1  - Isaias, Ioannis Ugo
A1  - Spiegel, Jörg
A1  - Brumberg, Joachim
A1  - Cosgrove, Kelly P.
A1  - Marotta, Giorgio
A1  - Oishi, Naoya
A1  - Higuchi, Takahiro
A1  - Küsters, Sebastian
A1  - Schiller, Markus
A1  - Dillmann, Ulrich
A1  - van Dyck, Christopher H.
A1  - Buck, Andreas
A1  - Herrmann, Ken
A1  - Schloegl, Susanne
A1  - Volkmann, Jens
A1  - Lassmann, Michael
A1  - Fassbender, Klaus
A1  - Lorenz, Reinhard
A1  - Samnick, Samuel
T1  - Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease
JF  - Frontiers in Aging Neuroscience
N2  - We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson's disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([(123)I]5IA). Patients were selected according to several criteria, including short duration of motor signs (<7 years) and normal scores at an extensive neuropsychological evaluation. In PD patients, nAChR density was significantly higher in the putamen, the insular cortex and the supplementary motor area and lower in the caudate nucleus, the orbitofrontal cortex, and the middle temporal gyrus. Disease duration positively correlated with nAChR density in the putamen ipsilateral (ρ = 0.56, p < 0.05) but not contralateral (ρ = 0.49, p = 0.07) to the clinically most affected hemibody. We observed, for the first time in vivo, higher nAChR density in brain regions of the motor and limbic basal ganglia circuits of subjects with PD. Our findings support the notion of an up-regulated cholinergic activity at the striatal and possibly cortical level in cognitively intact PD patients at an early stage of disease.
KW  - nicotinic receptors
KW  - Parkinson disease
KW  - 5IA-SPECT
KW  - dopamine acetylcholine
KW  - cognitive decline
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119351
VL  - 6
ER  - 
TY  - JOUR
A1  - Kreissl, Michael C.
A1  - Hänscheid, Heribert
A1  - Löhr, Mario
A1  - Verburg, Frederik A.
A1  - Schiller, Markus
A1  - Lassmann, Michael
A1  - Reiners, Christoph
A1  - Samnick, Samuel S.
A1  - Buck, Andreas K.
A1  - Flentje, Michael
A1  - Sweeney, Reinhart A.
T1  - Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
N2  - Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the strong expression of somatostatin receptors, peptide receptor radionuclide therapy (PRRT) has been used in advanced cases. We assessed the feasibility and tolerability of a combination of both treatment modalities in advanced symptomatic meningioma. Methods: 10 patients with irresectable meningioma were treated with PRRT (177Lu-DOTA0,Tyr3 octreotate or - DOTA0,Tyr3 octreotide) followed by external beam radiotherapy (EBRT). EBRT performed after PRRT was continued over 5–6 weeks in IMRT technique (median dose: 53.0 Gy). All patients were assessed morphologically and by positron emission tomography (PET) before therapy and were restaged after 3–6 months. Side effects were evaluated according to CTCAE 4.0. Results: Median tumor dose achieved by PRRT was 7.2 Gy. During PRRT and EBRT, no side effects>CTCAE grade 2 were noted. All patients reported stabilization or improvement of tumor-associated symptoms, no morphologic tumor progression was observed in MR-imaging (median follow-up: 13.4 months). The median pre-therapeutic SUVmax in the meningiomas was 14.2 (range: 4.3–68.7). All patients with a second PET after combined PRRT + EBRT showed an increase in SUVmax (median: 37%; range: 15%–46%) to a median value of 23.7 (range: 8.0–119.0; 7 patients) while PET-estimated volume generally decreased to 81 ± 21% of the initial volume. Conclusions: The combination of PRRT and EBRT is feasible and well tolerated. This approach represents an attractive strategy for the treatment of recurring or progressive symptomatic meningioma, which should be further evaluated.
KW  - Medizin
KW  - PRRT
KW  - Peptide receptor radionuclide therapy
KW  - Meningioma
KW  - Radiotherapy
KW  - EBRT
KW  - Combination
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75540
ER  -